Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Adjuvant System AS01 is a liposome-based vaccine adjuvant containing 3-O-desacyl-4′-monophosphoryl lipid A and the saponin QS-21. AS01 has been selected for the clinical development of several candidate vaccines including the RTS,S malaria vaccine and the subunit glycoprotein E varicella zoster vaccine (both currently in phase III). Given the known immunostimulatory properties of MPL and QS-21, the objective of this study was to describe the early immune response parameters after immunization with an AS01-adjuvanted vaccine and to identify relationships with the vaccine-specific adaptive immune response. Cytokine production and innate immune cell recruitment occurred rapidly and transiently at the muscle injection site and draining lymph node postinjection, consistent with the rapid drainage of the vaccine components to the draining lymph node. The induction of Ag-specific Ab and T cell responses was dependent on the Ag being injected at the same time or within 24 h after AS01, suggesting that the early events occurring postinjection were required for these elevated adaptive responses. In the draining lymph node, after 24 h, the numbers of activated and Ag-loaded monocytes and MHCIIhigh dendritic cells were higher after the injection of the AS01-adjuvanted vaccine than after Ag alone. However, only MHCIIhigh dendritic cells appeared efficient at and necessary for direct Ag presentation to T cells. These data suggest that the ability of AS01 to improve adaptive immune responses, as has been demonstrated in clinical trials, is linked to a transient stimulation of the innate immune system leading to the generation of high number of efficient Ag-presenting dendritic cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, these results have been obtained in young mice, and it is still not known if this mechanisms are preserved in aged animals [174].”
From Aging of the immune system: Focus on inflammation and vaccination (2016) · cites this paper as [174]
Citations
Cites
Neutrophils in the activation and regulation of innate and adaptive immunity
Mantovani, A., Cassatella, M. A., Costantini, C., & Jaillon, S. (2011) · Nature Reviews Immunology · doi:10.1038/nri3024 · Cited by 3,027
Arnold, L., Henry, A., Poron, F., Baba-Amer, Y., van Rooijen, N., Plonquet, A., Gherardi, R. K., & Chazaud, B. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070075 · Cited by 2,002
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
Jung, S., Unutmaz, D., Wong, P., Sano, G.-I., De los Santos, K., Sparwasser, T., Wu, S., Vuthoori, S., Ko, K., Zavala, F., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00365-5 · Cited by 1,773
Blood Monocytes: Development, Heterogeneity, and Relationship with Dendritic Cells
Auffray, C., Sieweke, M. H., & Geissmann, F. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132557 · Cited by 1,655
Kool, M., Soullié, T., van Nimwegen, M., Willart, M. A. M., Muskens, F., Jung, S., Hoogsteden, H. C., Hammad, H., & Lambrecht, B. N. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071087 · Cited by 993
Self-citationFirst Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
The RTS, S. C. T. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102287 · Cited by 896
Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901474 · Cited by 758
Self-citationA Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
The RTS, S. C. T. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208394 · Cited by 752 · cited 2×
“Recently, the RTS,S vaccine was shown to confer protection of 30–47% against uncomplicated and severe malaria in young African children and infants, respectively (17, 18).”
BackgroundHEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes
Girard, J.-P., Moussion, C., & Förster, R. (2012) · Nature Reviews Immunology · doi:10.1038/nri3298 · Cited by 713
Cited by
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., Levin, M. J., McElhaney, J. E., Poder, A., Puig-Barberà, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501184 · Cited by 1,454
Correlates of adjuvanticity: A review on adjuvants in licensed vaccines
Del Giudice, G., Rappuoli, R., & Didierlaurent, A. M. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.05.001 · Cited by 610
Self-citationAdjuvant system AS01: helping to overcome the challenges of modern vaccines
Didierlaurent, A. M., Laupèze, B., Di Pasquale, A., Hergli, N., Collignon, C., & Garçon, N. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2016.1213632 · Cited by 516
“Concentrations of cytokines in muscle and draining lymph node after injection with AS01 and gE antigen (data from [34]).”
BackgroundSelf-citationThe how’s and what’s of vaccine reactogenicity
Hervé, C., Laupèze, B., Del Giudice, G., Didierlaurent, A. M., & Tavares Da Silva, F. (2019) · npj Vaccines · doi:10.1038/s41541-019-0132-6 · Cited by 513
Self-citationAging of the immune system: Focus on inflammation and vaccination
Pinti, M., Appay, V., Campisi, J., Frasca, D., Fülöp, T., Sauce, D., Larbi, A., Weinberger, B., & Cossarizza, A. (2016) · European Journal of Immunology · doi:10.1002/eji.201546178 · Cited by 439
Designing spatial and temporal control of vaccine responses
Roth, G. A., Picece, V. C. T. M., Ou, B. S., Luo, W., Pulendran, B., & Appel, E. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00372-2 · Cited by 316
Systems analysis of protective immune responses to RTS,S malaria vaccination in humans
Kazmin, D., Nakaya, H. I., Lee, E. K., Johnson, M. J., van der Most, R., van den Berg, R. A., Ballou, W. R., Jongert, E., Wille-Reece, U., Ockenhouse, C., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621489114 · Cited by 293
“The RTS,S/AS01 vaccine candidate contains adjuvant system AS01, a liposomebased adjuvant comprising 3-O-desacyl-4′-monophosphoryl lipid A (MPL), a Toll-like receptor 4 ligand, and QS-21, a saponin extracted from the bark of the Quillaja saponaria Molina tree (5).”
An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy
Bonam, S. R., Partidos, C. D., Halmuthur, S. K. M., & Muller, S. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.002 · Cited by 261
“AS01 Liposomes containing MPLS and QS21 Activated Ag-loaded monocytes and MHC-II DCs [137]”
Coccia, M., Collignon, C., Hervé, C., Chalon, A., Welsby, I., Detienne, S., van Helden, M. J., Dutta, S., Genito, C. J., Waters, N. C., et al. (2017) · npj Vaccines · doi:10.1038/s41541-017-0027-3 · Cited by 260
“2B), confirming that AS01 rapidly activates innate immunity in the dLN.(7) The processes enriched by AS01 included those related to cytokines, such as interferons, MIF and IL-2.”
InfluentialSelf-citationControlling timing and location in vaccines
Irvine, D. J., Aung, A., & Silva, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.019 · Cited by 254
“These processes related to cell-mediated antigen trafficking are also induced by particulate adjuvants such as GSK’s liposomal adjuvant AS01b, which is comprised of liposomes with a size suitable for direct transport via lymphatics to the lymph node [69].”
Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines?
Ho, N. I., Huis in 't Veld, L. G. M., Raaijmakers, T. K., & Adema, G. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02874 · Cited by 216
“antigen-specific antibody responses and stimulates CD8+ T cells (6).”
BackgroundFrom discovery to licensure, the Adjuvant System story
Garçon, N., & Di Pasquale, A. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1225635 · Cited by 217
“These Adjuvant Systems induce local and transient innate responses, but of a different magnitude.(102,103) Correlated with its ability to induce a higher CMI response, AS01 induced a higher level of transient inflammation as compared to AS03 and AS04.”
ResultSelf-citationLiang, F., Lindgren, G., Sandgren, K. J., Thompson, E. A., Francica, J. R., Seubert, A., De Gregorio, E., Barnett, S., O’Hagan, D. T., Sullivan, N. J., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2094 · Cited by 209
“A consistent finding was that the vaccine distribution after deliverywas restricted to the site of infection and the draining LNs, which is in line with earlier mouse studies (14, 25, 26).”
ResultIdentification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants
Marty-Roix, R., Vladimer, G. I., Pouliot, K., Weng, D., Buglione-Corbett, R., West, K., MacMicking, J. D., Chee, J. D., Wang, S., Lu, S., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.683011 · Cited by 204
“However, it is conceivable that AS01 can signal through NLRP3 in vivo because IL-1 was detected in the muscle and draining lymph node upon immunization (73).”
Cunningham, A. L., Heineman, T. C., Lal, H., Godeaux, O., Chlibek, R., Hwang, S.-J., McElhaney, J. E., Vesikari, T., Andrews, C., Choi, W. S., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy095 · Cited by 204
“AS01B stimulates a local and transient activation of the innate response leading to the recruitment and activation of antigen-presenting dendritic cells [18].”
BackgroundHarbecke, R., Cohen, J. I., & Oxman, M. N. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab387 · Cited by 197
New-age vaccine adjuvants, their development, and future perspective
Verma, S. K., Mahajan, P., Singh, N. K., Gupta, A., Aggarwal, R., Rappuoli, R., & Johri, A. K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1043109 · Cited by 190
Lacaille-Dubois, M.-A. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.152905 · Cited by 177
“AS01 induces a rapid and transient activation of the innate immune system, both at the injection site and in the dLN, leading to the generation of high number of efficient Ag-loaded DCs in the dLN to promote Ag-specific adaptive immune responses (Didierlaurent et al., 2014) .”
A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity
Silva, M., Kato, Y., Melo, M. B., Phung, I., Freeman, B. L., Li, Z., Roh, K., Van Wijnbergen, J. W., Watkins, H., Enemuo, C. A., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abf1152 · Cited by 174
“This dose has been previously reported and is in line with FDA animals-to-human dosing conversion (81, 82).”
ResultFleck, J. D., Betti, A. H., Da Silva, F. P., Troian, E. A., Olivaro, C., Ferreira, F., & Verza, S. G. (2019) · Molecules · doi:10.3390/molecules24010171 · Cited by 160
Rondaan, C., Furer, V., Heijstek, M. W., Agmon-Levin, N., Bijl, M., Breedveld, F. C., D’Amelio, R., Dougados, M., Kapetanovic, M. C., van Laar, J. M., et al. (2019) · RMD Open · doi:10.1136/rmdopen-2019-001035 · Cited by 154
Burny, W., Callegaro, A., Bechtold, V., Clement, F., Delhaye, S., Fissette, L., Janssens, M., Leroux-Roels, G., Marchant, A., van den Berg, R. A., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00943 · Cited by 145
“By contrast, AS01 rapidly drained to the local lymph node (26), and 3 days after injection no signs of inflammation were detected at the injection sites of AS01-treated rabbits (75).”
BackgroundSelf-citationAdjuvant formulations for virus-like particle (VLP) based vaccines
Cimica, V., & Galarza, J. M. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.08.004 · Cited by 152
“MPL stimulates TLR4 with the subsequent induction of a Th1-mediated response and antibody production (see above), QS21 promotes antibody generation and CD8+ T cell activation, and the liposomes or emulsion stimulate antigen uptake from the APC such as dendritic cells [76,77].”
BackgroundVaccine development: From concept to early clinical testing
Cunningham, A. L., Garçon, N., Léo, O., Friedland, L. R., Strugnell, R. A., Laupèze, B., Doherty, M. T., & Stern, P. L. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.10.016 · Cited by 164
“nhance the adaptive response [39] Malaria vaccine, zoster vaccine”
BackgroundSelf-citationNeto, L. M. M., Kipnis, A., & Junqueira‐Kipnis, A. P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00239 · Cited by 138
“Their collaborative endeavors have been found to modulate (positively or negatively) the activity of different effector T cell subsets (53, 54) .”
BackgroundChitosan-Based Nanomaterial as Immune Adjuvant and Delivery Carrier for Vaccines
Gong, X., Gao, Y., Shu, J., Zhang, C., & Zhao, K. (2022) · Vaccines · doi:10.3390/vaccines10111906 · Cited by 155
“Lipid group compound adjuvant AS01 (liposome+MPL+QS21); AS15 (AS01+CpG); ISCOMs Effectively promotes CD4+ T lymphocyte-mediated immune response [68]”
BackgroundDetienne, S., Welsby, I., Collignon, C., Wouters, S., Coccia, M., Delhaye, S., Maele, L. V., Thomas, S., Swertvaegher, M., Detavernier, A., et al. (2016) · Scientific Reports · doi:10.1038/srep39475 · Cited by 135
Self-citationNatural and Synthetic Saponins as Vaccine Adjuvants
Wang, P. (2021) · Vaccines · doi:10.3390/vaccines9030222 · Cited by 133
Heineman, T. C., Cunningham, A. L., & Levin, M. J. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.02.009 · Cited by 141
Toward precision adjuvants: optimizing science and safety
Nanishi, E., Dowling, D. J., & Levy, O. (2020) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000868 · Cited by 135
Selection of adjuvants for vaccines targeting specific pathogens
Sarkar, I., Garg, R., & den Hurk, S. V. D. L. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1604231 · Cited by 122
“TLR5 signaling in CD103CD11bDCs plays an important role in intestinal IgA production and Th17 differentiation, and leads to MyD88-dependent, strong nuclear factor (NF)-κB activation and Th-2 type immune responses in mice [23,28].”
BackgroundMethodBorriello, F., Poli, V., Shrock, E. L., Spreafico, R., Liu, X., Pishesha, N., Carpenet, C., Chou, J. S., Gioia, M. D., McGrath, M. E., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.009 · Cited by 125
Overview of Vaccine Adjuvants: Introduction, History, and Current Status
Shah, R. R., Hassett, K. J., & Brito, L. A. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6445-1_1 · Cited by 147
“World in motion” – emulsion adjuvants rising to meet the pandemic challenges
O’Hagan, D. T., der Most, R. G. V., Lodaya, R. N., Coccia, M., & Lofano, G. (2021) · npj Vaccines · doi:10.1038/s41541-021-00418-0 · Cited by 131
The Matrix-M™ adjuvant: A critical component of vaccines for the 21 st century
Stertman, L., Palm, A.-K. E., Zarnegar, B., Carow, B., Lunderius-Andersson, C., Magnusson, S. E., Carnrot, C., Shinde, V., Smith, G., Glenn, G. M., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2189885 · Cited by 137
“and transiently at the injection site in the muscle, as well as in the dLNs (further discussed below).(26,28,30,31) Gene enrichment analysis in specific pathogen-free pigs that had received the research equivalent of the clinical-grade Matrix-M adjuvant (AbISCOR-100, Novavax AB) revealed that genes involved in inflamm…”
BackgroundResultInfluentialLeroux-Roels, G. G., Marchant, A., Lévy, J., Damme, P. V., Schwarz, T. F., Horsmans, Y., Jilg, W., Kremsner, P. G., Haelterman, E., Clément, F., et al. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.05.007 · Cited by 115
Self-citationDevelopment of adjuvanted recombinant zoster vaccine and its implications for shingles prevention
Lecrenier, N., Beukelaers, P., Colindres, R. E., Curran, D., Kesel, C. D., Saegher, J.-P. D., Didierlaurent, A. M., Ledent, E., Mols, J., Mrkvan, T., et al. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1495565 · Cited by 119
“Activated antigen-presenting cells carrying gE in the draining lymph node are responsible for the generation of high levels of gE-specific CD4+ T-cells and antibodies [59].”
BackgroundSelf-citationTowards an evidence based approach for the development of adjuvanted vaccines
O’Hagan, D. T., Friedland, L. R., Hanon, E., & Didierlaurent, A. M. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.07.010 · Cited by 107
Self-citationLysosome-Dependent Activation of Human Dendritic Cells by the Vaccine Adjuvant QS-21
Welsby, I., Detienne, S., N’Kuli, F., Thomas, S., Wouters, S., Bechtold, V., Wit, D. D., Gineste, R., Reinheckel, T., Elouahabi, A., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00663 · Cited by 117
“It is, however, unlikely that this mechanism contributes to lessened QS-21-elicited Ag-specific CD8 T cell responses observed in cathepsin B-deficient mice, since QS-21 and antigens display different localizations and pharmacokinetic properties after immunization (16).”
BackgroundMethodSelf-citationLocal innate immune responses in the vaccine adjuvant‐injected muscle
Liang, F., & Loré, K. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.19 · Cited by 115
Adjuvant system AS01: from mode of action to effective vaccines
Roman, F. P., Burny, W., Ceregido, M. A., Laupèze, B., Temmerman, S. T., Warter, L., & Coccia, M. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2382725 · Cited by 126
“Unlike other adjuvants such as emulsions or aluminum salts, AS01 does not directly enhance antigen uptake by monocytes or dendritic cells [26].”
InfluentialRecombinant Zoster Vaccine (Shingrix®): A Review in Herpes Zoster
Syed, Y. Y. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0603-x · Cited by 111
Th1 memory differentiates recombinant from live herpes zoster vaccines
Levin, M. J., Kroehl, M. E., Johnson, M. J., Hammes, A., Reinhold, D., Lang, N., & Weinberg, A. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121484 · Cited by 93
MPL Adjuvant Contains Competitive Antagonists of Human TLR4
Wang, Y., Bazin, H. G., Evans, J. T., Casella, C. R., & Mitchell, T. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577823 · Cited by 103
“Because MPL® is a highly purified derivative of the lipopolysaccharide (LPS) component of the cell-wall of Salmonella enterica its success as an adjuvant has been understood primarily in the context of its activity as an agonist of TLR4 that directly activates dendritic cells (8).”
BackgroundAdjuvant physiochemistry and advanced nanotechnology for vaccine development
Ren, H., Jia, W., Xie, Y., Yu, M., & Chen, Y. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00848c · Cited by 98
The science of vaccine adjuvants: advances in TLR4 ligand adjuvants
Reed, S. G., Hsu, F., Carter, D., & Orr, M. T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.06.007 · Cited by 90
RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap
Kaslow, D. C., & Biernaux, S. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.09.061 · Cited by 92
Lipopolysaccharide lipid A: A promising molecule for new immunity-based therapies and antibiotics
García-Vello, P., Lorenzo, F. D., Zucchetta, D., Zamyatina, A., Castro, C. D., & Molinaro, A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107970 · Cited by 97
Advanced technologies for the development of infectious disease vaccines
Gupta, A., Rudra, A., Reed, K., Langer, R., & Anderson, D. G. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01041-z · Cited by 100
“These adjuvants act by creating a locally inflamed environment at the injection site, which recruits immune cells 155 .”
Hajissa, K., Zakaria, R., Suppıan, R., & Mohamed, Z. (2019) · Journal of Advanced Veterinary and Animal Research · doi:10.5455/javar.2019.f329 · Cited by 85
“Therefore, uses of appropriate adjuvants are required to enhance their potency [42].”
BackgroundDevelopment of therapeutic vaccines for the treatment of diseases
Tian, Y., Hu, D., Li, Y., & Li, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00098-9 · Cited by 96
“) and cytokines, which subsequently recruit innate immune cells, including neutrophils, monocytes, macrophages and DCs, to the site of injection [36, 37].”
BackgroundVaccination in early life: standing up to the challenges
Mohr, E., & Siegrist, C. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.04.004 · Cited by 83
“Studies in mouse suggest that its efficacy results from enhanced DC and monocyte activation [49].”
BackgroundGillard, P. H., Yang, P., Danilovitš, M., Su, W., Cheng, S.-L., Pehme, L., Bollaerts, A., Jongert, E., Moris, P., Ofori‐Anyinam, O., et al. (2016) · Tuberculosis · doi:10.1016/j.tube.2016.07.005 · Cited by 90
Noh, Y., Kim, S., Kim, J., Kim, S., Ryu, J., Kim, I., Lee, E. J., Um, S. H., & Lim, Y. T. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201605398 · Cited by 78
Wang, Y., Lin, Y., Wang, J., Qiao, S., Liu, Y., Dong, W., Wang, J., An, H., Yang, C., Mamuti, M., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b00143 · Cited by 79
Burny, W., Marchant, A., Hervé, C., Callegaro, A., Caubet, M., Fissette, L. A., Gheyle, L., Legrand, C., N'Dour, C. T., Silva, F. T. D., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.02.015 · Cited by 78
“The kinetics of response observed in this clinical study is analogous to the responses observed in preclinical models with, for example, an early detection of IL-6 in the muscle and draining lymph nodes of mice, followed by a more prolonged IP-10 response [22,23], and of CRP in the serum of rabbits after administratio…”
BackgroundResultSelf-citationAdvancements in Vaccine Adjuvants: The Journey from Alum to Nano Formulations
Moni, S. S., Abdelwahab, S. İ., Jabeen, A., Elmobark, M. E., Aqaili, D. O., Gohal, G., Oraibi, B., Farasani, A., Jerah, A. A., Alnajai, M. M., et al. (2023) · Vaccines · doi:10.3390/vaccines11111704 · Cited by 105
“Ag-loaded dendritic cells and monocytes then lead to innate and humoral-mediated adaptive immunity [114].”
BackgroundThompson, E. A., Ols, S., Miura, K., Rausch, K. M., Narum, D. L., Spångberg, M., Juraska, M., Wille-Reece, U., Weiner, A. J., Howard, R. F., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120692 · Cited by 80
“respectively (42, 43), and AS01 induced IFN-related chemokines, such as CXCL10, in the draining LNs and injection sites of mice (44).”
BackgroundA Potent Cancer Vaccine Adjuvant System for Particleization of Short, Synthetic CD8+ T Cell Epitopes
He, X., Zhou, S., Huang, W., Seffouh, A., Mabrouk, M. T., Morgan, M. T., Ortega, J., Abrams, S. I., & Lovell, J. F. (2021) · ACS Nano · doi:10.1021/acsnano.0c07680 · Cited by 74
Mosquirix™ RTS, S/AS01 Vaccine Development, Immunogenicity, and Efficacy
Nadeem, A. Y., Shehzad, A., Islam, S. U., Al-Suhaimi, E. A., & Lee, Y. S. (2022) · Vaccines · doi:10.3390/vaccines10050713 · Cited by 80
Grupping, K., Campora, L., Douha, M., Heineman, T. C., Klein, N. P., Lal, H., Peterson, J., Vastiau, I., & Oostvogels, L. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix482 · Cited by 72
“Study Vaccines Study participants in both groups received 2 intramuscular doses of HZ/su 2 months apart.”
MethodLópez‐Fauqued, M., Cámpora, L., Delannois, F., Idrissi, M. E., Oostvogels, L., de Looze, F. J., Díez‐Domingo, J., Heineman, T. C., Lal, H., McElhaney, J. E., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.03.043 · Cited by 76
“However, pre-clinical evidence suggests that RZV is unlikely to cause long-term inflammation, as the innate immune response and activity of pro-inflammatory cytokines are transient [24].”
BackgroundResolving adjuvant mode of action to enhance vaccine efficacy
Turley, J. L., & Lavelle, E. C. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102229 · Cited by 71
Laupèze, B., Hervé, C., Pasquale, A. D., & Silva, F. T. D. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.07.098 · Cited by 75
Mot, L. D., Bechtold, V., Bol, V., Callegaro, A., Coccia, M., Essaghir, A., Hasdemir, D., Ulloa‐Montoya, F., Siena, E., Smilde, A. K., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8618 · Cited by 64
“Interferon (IFN)–related responses and increased C-reactive protein (CRP) and interleukin-6 (IL-6) concentrations correlated with adaptive responses and these markers were shared in recipients of the AS01- or AS03-adjuvanted vaccines (22), despite their distinct modes of action in mice (11, 12).”
BackgroundSelf-citationCunningham, A. L., McIntyre, P. B., Subbarao, K., Booy, R., & Levin, M. J. (2021) · BMJ · doi:10.1136/bmj.n188 · Cited by 75
Gershon, A. A. (2017) · Journal of Infection · doi:10.1016/s0163-4453(17)30188-3 · Cited by 73
Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants
Budroni, S., Buricchi, F., Cavallone, A., Bourguignon, P., Caubet, M., Dewar, V., D’Oro, U., Finco, O., Garçon, N., Idrissi, M. E., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00337-0 · Cited by 69
Self-citationKim, H., & Shin, S. J. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.891878 · Cited by 65
“, 2011), resulting in enhanced adaptive immunity (Didierlaurent et al., 2014).”
Backgroundvan den Berg, R. A., Coccia, M., Ballou, W. R., Kester, K. E., Ockenhouse, C. F., Vekemans, J., Jongert, E., Didierlaurent, A. M., & van der Most, R. G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00557 · Cited by 55
“In AS01, the combination of MPL and QS-21 enhances antibody and T-cell responses to vaccine antigens, potentially via the transient stimulation of the innate immune system which induces efficient antigen-presenting dendritic cells (12, 13).”
BackgroundSelf-citationSystems analysis of human vaccine adjuvants
Harandi, A. M. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.08.001 · Cited by 54
Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial
Wilkinson, T. M. A., Schembri, S., Brightling, C. E., Bakerly, N. D., Lewis, K. E., MacNee, W., Rombo, L., Hedner, J. A., Allen, M. B., Walker, P. P., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.07.100 · Cited by 56
“This may be due to enhanced activation of the innate immune response induced by the adjuvant at the injection site and increased production of cytokines and chemokines [23,31,32].”
Correlates of GLA family adjuvants’ activities
Reed, S. G., Carter, D., Casper, C., Duthie, M. S., & Fox, C. B. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.10.004 · Cited by 53
Larsen, S. E., Williams, B. D., Rais, M., Coler, R. N., & Baldwin, S. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.840225 · Cited by 52
“For example, clinical stage saponin-based adjuvant, AS01, composed of QS21 and TLR4 agonist MPL, leads to release of alarmins and subsequent DC activation in mice (57).”
BackgroundInfluentialChoi, A., Bouzya, B., Franco, K.-D. C., Stadlbauer, D., Rajabhathor, A., Rouxel, R. N., Mainil, R., der Wielen, M. V., Palese, P., García‐Sastre, A., et al. (2019) · ImmunoHorizons · doi:10.4049/immunohorizons.1900022 · Cited by 47
“Interestingly, AS01 induced higher levels of Ag-specific IgG2a, resulting in a higher IgG2a/IgG1 ratio, which is indicative of a Th1-focused immune response, in line with previous observations (39, 40).”
ResultMabrouk, M. T., Chiem, K., Rujas, E., Huang, W., Jahagirdar, D., Quinn, B., Nair, M. S., Nissly, R. H., Cavener, V. S., Boyle, N. R., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj1476 · Cited by 49
“While the mechanisms of the QS-21 and MPLA components of AS01 are still under investigation (20), they have been shown to elicit caspase-1–dependent interleukin-1 (IL-1) and IL-18 release in antigen-presenting cells such as macrophages and dendritic cells (21).”
BackgroundBiologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development
Schiffer, J. T., & Gottlieb, S. L. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.09.044 · Cited by 47
“Indeed, vaccine adjuvants that target dendritic cells, NK cells and macrophages are under intense study [114].”
BackgroundPlasmodium falciparum Malaria Vaccines and Vaccine Adjuvants
Bonam, S. R., Rénia, L., Tadepalli, G., Bayry, J., & Kumar, H. M. S. (2021) · Vaccines · doi:10.3390/vaccines9101072 · Cited by 57
Immune responses to zoster vaccines
Levin, M. J., & Weinberg, A. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1560918 · Cited by 47
The herpes zoster subunit vaccine
Cunningham, A. L. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1134481 · Cited by 46
“[26,32–34] The substantial immune response to HZ/su in both older and immunocompromised populations observed in phase I–II studies is mostly attributable to the ability of the AS01B Adjuvant System to boost VZV-specific memory immune responses.[22,35] Indeed, gE adjuvanted with AS01B elicits higher gE-specific CD4+ T…”
BackgroundKoker, S. D., Hoecke, L. V., Beuckelaer, A. D., Roose, K., Deswarte, K., Willart, M. A. M., Bogaert, P., Naessens, T., Geest, B. G. D., Saelens, X., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06236-6 · Cited by 46
Self-citationCunningham, A. L., & Levin, M. J. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy382 · Cited by 50
“A subunit vaccine (HZ/su) consisting of recombinant VZV glycoprotein E (gE) and the AS01B adjuvant system was developed by GlaxoSmithKline Vaccines (Wavre, Belgium).”
BackgroundInfluentialReview of the initial post-marketing safety surveillance for the recombinant zoster vaccine
Silva, F. T. D., Co, M. M., Dessart, C., Hervé, C., López‐Fauqued, M., Mahaux, O., Holle, L. V., & Stegmann, J. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.11.058 · Cited by 45
Bosteels, C., Fierens, K., Prijck, S. D., Moorleghem, J. V., Vanheerswynghels, M., Wolf, C. D., Chalon, A., Collignon, C., Hammad, H., Didierlaurent, A. M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.606805 · Cited by 45
“Given the hybrid features of inf-cDC2s, such as the expression of Ly6C and activating Fc receptors CD64 and MAR-1, these cells have been misclassified as migratory MCs with APC capacity in earlier studies (25, 27, 41).”
BackgroundMethodInfluentialSelf-citationNew perspectives for natural triterpene glycosides as potential adjuvants
Lacaille‐Dubois, M., & Wagner, H. (2017) · Phytomedicine · doi:10.1016/j.phymed.2017.10.019 · Cited by 39
“…pathogens including the RTS,S (a recombinant portion of the circumsporozoïte protein of Plasmodium falciparum fused to hepatitis B surface antigen) against malaria, the subunit glycoprotein E of varicella zoster virus, the HIV, and Mycobacterium tuberculosis (Didierlaurent et al., 2014, 2017).”
BackgroundYan, K., Vet, L. J., Tang, B., Hobson‐Peters, J., Rawle, D. J., Le, T. T., Larcher, T., Hall, R. A., & Suhrbier, A. (2020) · Vaccines · doi:10.3390/vaccines8030368 · Cited by 40
“The composition of this adjuvant and the dose used in mice has been published [45,46].”
Lofano, G., Mallett, C. P., Bertholet, S., & O’Hagan, D. T. (2020) · npj Vaccines · doi:10.1038/s41541-020-00238-8 · Cited by 45
Foamy Matters: An Update on Quillaja Saponins and Their Use as Immunoadjuvants
Magedans, Y. V. D. S., Yendo, A. C. A., de Costa, F., Gosmann, G., & Fett‐Neto, A. G. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0438 · Cited by 41
The quest for vaccine-induced immune correlates of protection against tuberculosis
Nemes, E., Fiore-Gartland, A. J., Boggiano, C., Coccia, M., D’Souza, P., Gilbert, P. B., Ginsberg, A. M., Hyrien, O., Laddy, D. J., Makar, K. W., et al. (2022) · Vaccine Insights · doi:10.18609/vac/2022.027 · Cited by 39
“AS01, the adjuvant used in the M72 vaccine, is known to potently activate the immune system [36].”
Backgroundvan den Berg, R. A., Mot, L. D., Leroux-Roels, G. G., Bechtold, V., Clément, F., Coccia, M., Jongert, E., Evans, T. G., Gillard, P. H., & der Most, R. G. V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00564 · Cited by 37
“In AS01 mode of action studies in mice, AS01 enhances adaptive immune responses to the vaccine antigen by triggering innate immune activity at the injection site and draining lymph node including the transient release of cytokines, the transient release of IFNG (which can also be detected in peripheral blood), the rec…”
BackgroundVaccine profile of herpes zoster (HZ/su) subunit vaccine
Cunningham, A. L., & Heineman, T. C. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1329012 · Cited by 39
“AS01B adjuvant system, containing 50 μg MPL and QS21 in liposomes [22,31].”
Antigen-stimulated PBMC transcriptional protective signatures for malaria immunization
Moncunill, G., Scholzen, A., Mpina, M., Nhabomba, A. J., Hounkpatin, A. B., Osaba, L., Valls, R., Campo, J. J., Sanz, H., Jairoce, C., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8924 · Cited by 39
“TLR4 is an innate receptor that recognizes pathogen-associated molecular patterns such as lipopolysaccharide (LPS) and induces proinflammatory responses through the canonical NF-B pathway and type I IFN responses through interferon regulatory factor 3 (IRF3) (both responses found in the BTMs associated with protection…”
BackgroundInfluentialEmerging adjuvants for intradermal vaccination
Chen, X. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122559 · Cited by 40
“AS01 also induced rapid recruitment of neutrophils and monocytes into adjuvant-injected muscle [43].”
BackgroundInfluentialBaldwin, S. L., Reese, V. A., Larsen, S. E., Beebe, E. A., Guderian, J. A., Orr, M. T., Fox, C. B., Reed, S. G., & Coler, R. N. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247990 · Cited by 36
“This data is in line with the AS01 adjuvant system, which has been shown to require MHCII DC’s for priming optimal adaptive T cell responses [28].”
ResultFochesato, M., Dendouga, N., & Boxus, M. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1154247 · Cited by 35
Self-citationNeeland, M. R., Shi, W., Collignon, C., Taubenheim, N., Meeusen, E. N. T., Didierlaurent, A. M., & de Veer, M. J. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600817 · Cited by 33
“Similar effects have been described in humans (19) and other models, including mice (7), demonstrating that the sheep model is relevant for further study investigating the mode of action of AS01.”
BackgroundInfluentialSelf-citationAndreas, S., Testa, M., Boyer, L., Brusselle, G., Janssens, W., Kerwin, E., Papi, A., Pek, B., Puente‐Maestu, L., Saralaya, D., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00502-6 · Cited by 33
Feed Additives in Aquaculture: Benefits, Risks, and the Need for Robust Regulatory Frameworks
Okon, E. M., Iyobhebhe, M. E., Olatunji, P. O., Adeleke, M., Matekwe, N., & Okocha, R. C. (2025) · Fishes · doi:10.3390/fishes10090471 · Cited by 40
Avidity of Anti-Circumsporozoite Antibodies following Vaccination with RTS,S/AS01E in Young Children
Olotu, A., Clément, F., Jongert, E., Vekemans, J., Njuguna, P., Ndungu, F. M., Marsh, K., Leroux-Roels, G. G., & Bejon, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115126 · Cited by 36
“Potent novel adjuvant (AS01) co-administered with the vaccine and the virus-like particle nature of the RTS,S may explain the high avidity observed in comparison with other studies [28, 29].”
ResultLeroux-Roels, G. G., Damme, P. V., Haazen, W., Shakib, S., Caubet, M., Aris, E., Devaster, J., & Peeters, M. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.04.051 · Cited by 34
Metadata
- Authors
- Didierlaurent, A. M., Collignon, C., Bourguignon, P., Wouters, S., Fierens, K., Fochesato, M., Dendouga, N., Langlet, C., Malissen, B., Lambrecht, B. N., Garçon, N., Van Mechelen, M., & Morel, S.
- Affiliations
- GlaxoSmithKline (Belgium) (BE)
- Vlaams Instituut voor Biotechnologie (BE)
- Centre National de la Recherche Scientifique (FR)
- GlaxoSmithKline Vaccines , 1330 Rixensart ,
- Corresponding author
- Collignon, Catherine
- Bourguignon, Patricia
- Wouters, Sandrine
- Fochesato, Michel
- Dendouga, Najoua
- Langlet, Christelle
- Morel, Sandra
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-08
- Volume
- 193
- Issue
- 4
- Pages
- 1920-1930
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1942950379
- Cited by
- 266
- References
- 56
- Citations by year
- 2026: 14 · 2025: 25 · 2024: 15 · 2023: 23 · 2022: 31 · 2021: 26 · 2020: 19 · 2019: 28 · 2018: 14 · 2017: 37 · 2016: 21 · 2015: 10 · 2014: 2
- FWCI
- 10.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- MPL, QS-21, dendritic cells, adaptive immune response, antigen presentation, MHC class II, monocytes, draining lymph nodes, cytokine production, innate immune activation, RTS,S malaria vaccine, varicella-zoster vaccine, T cell response, antibody response
- MeSH terms
- Adjuvants, Immunologic, Animals, Histocompatibility Antigens Class II, B-Lymphocytes, Dendritic Cells, Drug Combinations, Female, Humans, Lipid A, Lymphocyte Activation, Mice, Inbred C57BL, Monocytes, Saponins, Vaccination, Vaccines, CD4-Positive T-Lymphocytes, Antigen Presentation, CD8-Positive T-Lymphocytes, Mice, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.